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Background: Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm, described in several locations in the
body. It is classified as intermediate malignant potential with low risk of metastasis and has a low tendency to recur
after primary surgery.
Methods: We performed a prospective data collection of the patients with SFT presented to the Royal Marsden
Hospital from January to December 2013, and treated with pazopanib in first line. Demographics, anatomic primary
sites, treatment and survival outcomes were collected from patients’ electronic records.
Results: 13 patients (54% females) were identified with a median age of 51 years (range 37–77). Most of the
patients (77%) were diagnosed with extra-thoracic SFT. All the patients received first line treatment with pazopanib
for metastatic disease. Median overall survival (OS) was 13.3 months. Median progression free survival (PFS) was
4.7 months. No statistically significant difference was found in OS and PFS between primary thoracic SFT and
primary extra-thoracic SFT. According to RECIST, one partial response (9%) and eight disease stabilizations (73%)
were found as best responses. Using Choi criteria, there were 5 partial responses (46%) and 4 stabilizations (36%).
Conclusion: Our prospective data confirm that anti-angiogenic drugs are active in SFT. PFS and overall response do
not appear significantly lower than other reported series on the same disease. Furthermore, pazopanib is a drug already
licensed in soft tissue sarcomas and these data suggest its activity also in this particular subtype of sarcomas.
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Solitary Fibrous Tumour (SFT) is a rare soft tissue neo-
plasm, initially thought to occur exclusively within the
thorax [1] and now known to arise from all anatomical
sites [2]. In the past, SFT has also been called hemangio-
pericytoma, a term used over the years to describe a
wide variety of tumours with some common morpho-
logical characteristics. Different biological entities have
progressively been identified for this category, and most
of them are now recognized as SFTs [3].
Recently, STFs have been described in several loca-
tions also outside the thoracic cavity, including head and* Correspondence: charlotte.benson@rmh.nhs.uk
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unless otherwise stated.neck, abdomen, retroperitoneum, and other soft tissue
sites [4-6].
SFTs are classified as having intermediate malignant
potential with low risk of metastasis under the WHO
classification [7] and they have a low tendency to recur
after primary surgery [8]. However, the clinical behav-
iour is hard to predict and several prognostic factors
have been considered in order to assess the behaviour of
the disease. In a recent analysis of a large cohort of
SFTs, the size and the mitotic index have been proposed
as factors to consider after primary surgery which may
help to stratify the follow-up of the patients that might
have an increased risk of recurrence [5]. Generally, treat-
ment for metastatic SFTs is not curative and is of pallia-
tive intent.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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small series, with conflicting results but overall indicating
limited efficacy [9-12]. Recently, the role of dacarbazine in
SFT has been investigated within a large mono-institutional
case series with positive results [13]. Also the activity of
temozolamide and bevacizuamb has been reported [14]
and other antiangiogenic drugs have shown some activity,
such as sorafenib [15] and sunitinib [16].
Pazopanib is as a second-generation small-molecule,
potent and selective multi-targeted receptor tyrosine
kinase inhibitor (TKI) active against vascular endothelial
growth factor receptors (VEGFR) 1, 2, and 3, platelet-
derived growth factor receptors (PFGFR), and KIT. It
also has modest activity against fibroblast growth factor
receptors (FGFR) 1, 2, and 3 [17]. Its activity blocks
tumour growth and inhibits angiogenesis. It is now ap-
proved for first line treatment in kidney cancer [18] and
for second or further line in non-adipocytic soft tissue
sarcomas after failure of previous chemotherapy [19].
In this paper we report our experience on the manage-
ment of SFT with a group of 13 patients prospectively
collected and treated with pazopanib as a first line treat-
ment for metastatic disease.
Methods
We prospectively collected data from all consecutive
patients with histologically confirmed advanced SFT, who
were treated with pazopanib as first-line systemic treat-
ment at the Royal Marsden Hospital, from January to De-
cember 2013. Demographics, site, treatment, toxicities and
survival outcomes were collected from electronic patients’
records. Toxicity was recorded according to CTCAE v4.0
criteria, while disease response was assessed with repeated
computerised tomography (CT) scan and or magnetic res-
onance imaging (MRI) every two or three months. Re-
sponse was assessed according to RECIST version 1.1 [20]
and Choi criteria [21] by a named sarcoma radiologist
(CM). Histological diagnosis of SFT was reviewed and con-
firmed in all cases by an experienced sarcoma pathologist.
Ethical approval was provided by relevant Committee
at the Royal Marsden Hospital.
For statistical analysis, progression free survival (PFS) was
defined from date of starting chemotherapy to date of pro-
gression or death where any progression free surviving pa-
tients were censored at last follow up; overall survival (OS)
was defined from date of starting chemotherapy to date of
death where any surviving patients were censored at last
follow up. Statistical analysis was conducted with Kaplan-
Meier method by a designated Sarcoma Unit statistician.
Results
Demographics
Thirteen consecutive patients were seen at the Royal
Marsden Hospital in 2013 with diagnosis of symptomaticmetastatic SFT and treated with pazopanib. The majority
of them were women (54%) with a median age of
51 years (range 37–77). Most of the patients (77%) were
diagnosed with extra-thoracic SFT; predominant primary
sites were abdomen, pelvis, spine, thighs and thorax. All
the patients had an ECOG (Eastern Cooperative Oncol-
ogy Group) performance status between 0 and 2. All the
patients had documented radiological progressive dis-
ease within three months prior to starting on pazopanib.
Patient demographics and prior management are sum-
marised in Table 1.
Treatment
Eight patients (72%) underwent surgery of the primary
tumour; one of them received several surgical resections
of primary disease and small single metastases. Five pa-
tients (28%) were deemed unresectable at presentation.
All the patients received first line pazopanib for meta-
static disease. 8 (62%) patients started with full dose of
Table 3 Treatment related toxicities (CTCAE version 4.0)
G1/G2 G3/G4
Intratumoral bleeding - 1 (7%)
Haemoperitoneum - 1 (7%)
Multiple kidney infarct - 1 (7%)
Skin reactions 5 (38%) 1 (7%)
Fatigue 10 (77%) -
Diarrhoea 5 (38%) -
Dysgeusia 4 (31%) -
Nausea 3 (24%) -
Mucositis 3 (24%) -
Anorexia 3 (24%) -
Liver function test alteration 2 (15%) -
Neutropenia 1 (7%) -
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of 600 mg daily based on physicians’ assessment, mainly
because of performance status. Three patients (23%)
required dose reduction because of grade 3 or persistent
grade 2 side effects, no-one required more than one
dose reduction during the treatment. The median dur-
ation of the treatment was 4.1 months (range 0.95-22.2).
85% of the patients (11) were discontinued from the
treatment because of disease progression (9, 69%) or
toxicities (2, 15%). Two patients (15%) are still on the
treatment at the time of this report. Treatment response
is summarized in Table 2.
Toxicities
All the patients experienced grade 1 or 2 toxicities.
Grade 3 to 4 toxicities were reported sporadically: one
patient (7%) experienced haemoperitoneum and another
two (15%) had intratumoural bleeding, one patient (7%)
had grade 3 liver function test alteration, which resolved
with dose reduction, one experienced a grade 3 hand
foot skin reaction, one patient (7%) had multiple kidney
infarcts without renal function alteration. Two patients
discontinued the treatment because of severe adverse
events: one because of massive haemoperitoneum, the
second one because of grade 3 skin toxicity. No toxic
deaths were reported. All the toxicities are summarized
in Table 3.
Radiological response
Eleven out of 13 patients were assessable for response
according to RECIST and Choi criteria. According to
RECIST, the assessments showed one partial response
(9%), eight disease stabilizations (73%), and two disease
progression (18%) as best responses. Compared to these
results, with Choi criteria there was a greater number ofTable 2 Best response to treatment






1 M 45 not assessable not assessable 4.1
2 M 46 SD SD 39.3
3 F 73 SD PR 10.7
4 F 69 PD PD 13.0
5 F 57 not assessable not assessable 2.0
6 M 49 PD PD 7.0
7 F 68 PR PR 20.3
8 M 37 SD SD 95.1
9 F 66 SD PR 60.0
10 F 37 SD PR 19.7
11 M 32 SD PR 17.4
12 M 77 SD SD 10.0
13 F 51 SD SD 21.9partial responses (5, 46%), a smaller number of stable
diseases (4, 36%), and the same number of progressions
(2, 18%). Two patients were not assessable either with
RECIST or Choi criteria because of early discontinuation
before radiological assessment due to severe side effects.
Survival
11 out of 13 patients progressed during the treatment
with pazopanib and were discontinued. For two patients
the treatment is still ongoing. With a median follow-up
time of 12.3 months, median progression free survival
(PFS) was 4.7 months (95% CI 4.8-7.4). The 6-month
progression-free rate was 44.9% (Figure 1). Median over-
all survival (OS) was 13.3 months (95% CI 3.9-22.6). The
6-month overall surival rate was 66.9% (Figure 2).
Median PFS and OS for the subgroup of primary thor-
acic SFT were 9.0 and 11.5 months respectively, com-
pared to 3.1 and 13.3 months respectively in the primary
extra-thoracic subgroup, with no statistical significance
in the comparison (p = 0.773 and p = 0.437, respectively).
Discussion
Since January 2013, 13 patients with progressive SFT have
been treated at the Royal Marsden Hospital with continu-
ous dosing pazopanib. This is a prospective collection of
data of all consecutive patients treated in the same way in
a single institution. Among the 11 patients assessable for
response, the clinical benefit rate (partial response + dis-
ease stabilisation) was the same (82%) using both RECIST
and Choi criteria. The outcome of the patients in our
series suggests that pazopanib is an active treatment in
advanced SFT. This is consistent with the results achieved
with other anti-angiogenic therapies already reported in
the literature. However, our series show some significative
differences.
For instance, Stacchiotti et al. [16] focused on the treat-
ment of SFT with sunitinib. Among a large cohort of 31
Figure 1 Progression free survival: median rate 4.7 months (95% CI 1.8 – 7.4); 6-month rate 44.9% (95% CI 17.7 – 69.0).
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ease compared to this series, and a lower overall response
rate. However, interestingly, in that series the median PFS
was 6.0 months whereas it was 4.7 months in our patients.
Similarly to us, they found sunitinib to be active in SFT,
with possible long lasting disease control.
The French Sarcoma Group recently reported their ex-
perience with sorafenib, another small molecule antian-
giogenic drug [22]. Among five patients, they found no
objective response, with a median overall survival of
less than 20 months, but with some evidence of disease
stabilisation.
Similar results were reported from a single cancer centre,
10 patients received sunitinib or pazopanib as a second orFigure 2 Overall Survival median rate 13.3 months (95% CI 3.9 – 22.6further line of treatment, with a median PFS of 5.2 months
and overall an acceptable toxicity profile [23].
The MD Anderson Cancer Centre reported on the ef-
ficacy of an anti-angiogenetic drug combination for SFT
[14]. Temozolamide plus bevacizumab produced a Choi
partial response in 11 patients (79%) with hemangioperi-
cytoma and malignant SFT, two patients (14%) had
stable disease and one patient (7%) had progressive dis-
ease. The estimated median PFS was 9.7 months with a
6-month progression-free rate of 78.6%.
The role of chemotherapy has also been investigated.
Our group [12] reported of 17 SFT patients treated with
anthracycline-based chemotherapy, in whom there was
only 1 partial response, and most of the patients had); 6-month rate 63.9% (95% CI 29.3 – 85.0).










Sunitinib (Stacchiotti) 31 6.4% NR 16.0 6.0
Sorafenib (FSG) 5 0% NR 19.7 NR
Antiangiogenic drugs (Levard) 10 0% NR NR 5.1
Temozolamide and
Bevacizumab (Park)
14 NR 79% NR 9.7
Dacarbazine (Stacchiotti) 8 37.5% NR NR 7.0
Anthracycline (Costantinidou) 17 5.8% NR 14.6 4.2
Chemotherapy (Levard) 23 9% NR NR 5.2
Pazopanib (present study) 13 9% 46% 13.3 4.7
(mos =months, NR = not reported, pts = number of patients,
RR = response rate).
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and OS was 14.6 months. The study was interpreted as
showing that chemotherapy was of little value in ad-
vanced SFT, however the median PFS, OS and likelihood
of response according to RECIST were little different
from the results with pazopanib, emphasising the need
for caution in interpreting the results from small series,
and demonstrating the need for larger, prospective phase
II trials in this disease.
Another group of authors has reported on the out-
come of SFT treated with dacarbazine [13] showing the
antitumor activity of this drug in SFT. Among 8 patients
treated, they found 3 partial responses and only one
progressive disease, with a median PFS of 7 months.
The same French group who reported on antiangio-
genic drugs, also reported their experience with chemo-
therapy [23]. They treated 23 patients in first line with
different chemotherapy regimens, mainly containing anthra-
cycline (18 out of 23). The median PFS was 5.1 months,
with 2 partial responses (9%) and 13 stabilizations (57%) as
best response.
A comparison among the survival outcome from all
the studies conducted so far for metastatic SFT is reported
in Table 4.Figure 3 An example of Choi response to the treatment: (a) baselineIn summary, and compared to the largest recent series
reported, our data confirm that pazopanib has some
activity against SFT. A number of agents appear to be
capable of inducing genuine disease stabilisation. Our
experience and that of the group at MD Anderson sug-
gests that consideration should be given to evaluation of
response using Choi criteria rather than RECIST. Several
studies suggested that Choi could be a more sensitive
tool to evaluate disease response in sarcoma, especially
in gastrointestinal stromal tumours [21,24,25], and there
is some evidence for its use in non GIST sarcomas
[26,27]. A significant obstacle to the widespread intro-
duction of these criteria is the limited reproducibility.
However some of the challenges of Choi criteria such
as the need to avoid areas of fistula and obtaining repro-
ducible measurements on mobile small bowel lesions
are more common in GIST and use in non GIST sarco-
mas is therefore often less problematic. The use of Choi
criteria, with the double assessment of density and
size, requires increased time of an experienced sarcoma
radiologist to report all examinations for the same
patient and consistent CT protocols at each follow-up
time point. Implementation of Choi criteria in a non-
oncologic hospital, with lack of expertise may not be
possible. Anyway, Choi criteria were overall able to
better appreciate the response, since they are based on
changes in contrast enhancement on CT, which reflects
tumour blood flow, as well as tumour size, which may
not alter greatly with these agents. We assessed the ac-
tivity of pazopanib both with RECIST and Choi. Since
Choi criteria are more stringent in the definition of pro-
gression, we were not concerned about failing to iden-
tify treatment failure. and indeed when RECIST showed
progressive disease this was confirmed by Choi. Simi-
larly, in 4 cases (36%) of stable disease by RECIST,
partial response could be detected by Choi, with a sig-
nificant reduction of attenuation on CT (Figure 3). For
future studies Choi criteria should be incorporated as
part of the disease assessment as well as RECIST as a
better indication of disease modulation by agents such
as pazopanib.HU 43; (b) after six months of treatment HU 35.
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acceptable treatment. Most of our patients experienced
grade 1 to 2 toxicities and only a few of them had severe
side effects The toxicity profile in our cohort of SFT is
in line with the result from the phase III registration trial
of pazopanib in soft tissue sarcoma [19]. The most com-
mon adverse events reported with pazopanib in treating
sarcomas were fatigue, diarrhoea, nausea, weight loss,
and hypertension. From our series, fatigue, diarrhoea,
and skin reaction were the most common side effects.
Interestingly, only a small number of grade 3 or 4 side
effects were observed.
In terms of further research, a phase II trial, to be
performed by the Spanish Sarcoma Group together with
French and Italian Centres, is due to investigate the role
of pazopanib in SFT (NCT 02066285). An American
study in advanced sarcoma with dasatinib included
patients with SFT (NCT 00464620) and final data are
awaited. We are recruiting to a translational research
study with pazopanib which will include patients with
SFT utilizing tumour biopsies. In this way, we want to
search for molecular targets or specific pathways able to
help in understanding which patients could most benefit
from these treatments.
Overall, our data confirm that anti-angiogenic agents
have some activity against SFT. Pazopanib is licensed for
the treatment of soft tissue sarcomas and hence is
available for treating this particular subtype. However, in
spite of the evidence that disease stabilisation and some-
times objective response can be achieved in a percentage
of patients, median PFS and OS are remarkably similar
across the various reports indicating the need for a more
effective approach to the systemic management of this
disease.
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